APPROVED FOR THE TREATMENT OF IPF, SSc-ILD AND PF-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
Most common GI-related adverse events with OFEV® are mild to moderate and effectively managed in SSc-ILD
Document ID: PC-MY-102713
20/09/2022
Author: Boehringer Ingelheim
The clinical efficacy and safety of OFEV® has been studied in patients with SSc-ILD (SENSCIS®) and IPF (INPULSIS -1 and -2) with consistent effects in slowing disease progression and no new safety signals.1-3
References:
1. Distler O, et al. N Engl J Med. 2019;380(26):2518-2528.
2. Richeldi L, et al. N Engl J Med. 2014;370(22):2071-2082.
3. Richeldi L, et al. Respir Med. 2016;113:74-79.
RELATED CONTENT
PC-MY-102713
Production date: September 2022
Production date: September 2022